Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro

Potentiation of the Effect of Paclitaxel and Carboplatin by Antioxidant Mixture on Human Lung Cancer H520 Cells

“…The effective in vitro dose of paclitaxel has been reported to be 0.05 to 0.1 mol [16] and that of carboplatin is 0.5-1.5 g/mL [17]. The results of MTT assay in our study revealed that the total cell death in H520 cells remains uniform (approximately 88% with paclitaxel and approximately 22% with carboplatin) over the entire effective dose range of these agents.…”

“…Similarly, the effective and non-toxic dose of carboplatin reported in vitro is 0.5-1.5 g/mL [17]. Two dose levels of antioxidant mixture were used in our study (Table 1).…”

The additive damage model: A mathematical model for cellular responses to drug combinations

“…Results are shown for two data sets (numbers 24 and 35 in Figure 2): those of Engblom et al (22) for cisplatin and paclitaxel acting on SK-OV-3 ovarian carcinoma cells and those of Nakamura et al (37) for the trastuzumab (Herceptin®) – ZD1839 (Iressa®) combination acting on A549 small cell lung carcinoma cells. These examples are chosen to illustrate typical differences between models in their ability to fit experimental data sets.…”

“…Twenty-four suitable data sets were identified for platinum-taxane drug combinations. These included data for cisplatin/paclitaxel (18–21), cisplatin/docetaxel (18), carboplatin/paclitaxel and carboplatin/docetaxel (22). An additional 21 data sets for a variety of drug combinations were collected: 5-fluorouracil/aclarubicin hydrochloride (23); 5-fluorouracil/fleroxacin (24); 5-fluorouracil/mitomycin-C (23); acivicin/asparaginase (25); aclarubicin hydrochloride/mitomycin-C (23); cyclophosphamide and thiotepa (26); erlotinib/rapamycin (27); gemcitabine/TRA-8 (28); imatinib/rapamycin (29); trastuzumab/ZD1839 (30) (31); gemcitabine/OBP-301(32).…”

Paclitaxel in the Treatment of Retinal Tumors of LH beta-Tag Murine Transgenic Model of Retinoblastoma

“…11,12 In one recent study, a combination of paclitaxel and carboplatin was used to successfully treat metastatic choriocarcinoma. 10 In addition, results of a randomized phase III trial, published in 2003, demonstrated that paclitaxel in combination with carboplatin and etoposide is superior to the standard chemotherapy regimen (i.e., carboplatin, etoposide, and vincristine) in patients with small-cell lung cancer.…”